Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study.

Jonathan BrettBenjamin DanielsEmily A KarangesNicholas A BuckleyCarl SchneiderAtheer NassirAndrew J McLachlanSallie-Anne Pearson

Published in: British journal of clinical pharmacology (2017)

Psychotropic polypharmacy is common, despite limited evidence of risks and benefits. Increases in polypharmacy with multiple prescribers may be due to poor communication with patients and between health care professionals.

Keyphrases

healthcare
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
adverse drug
peritoneal dialysis
prognostic factors
cross sectional
patient reported outcomes
patient reported
drug induced